DNA repair: Exploiting the fanconi anemia pathway as a potential therapeutic target

Physiological Research

Volumn 60, Issue 3, 2011, Pages 453-465

  Hucl, T ^a   Gallmeier, E ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

DNA damage; DNA repair; Fanconi anemia; Synthetic lethality; Targeted therapy

Indexed keywords

EID: 79960958032     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932115     Document Type: Review

References (92)

1. AALTONEN LA, SALOVAARA R, KRISTO P, CANZIAN F, HEMMINKI A, PELTOMAKI P, CHADWICK RB, KAARIAINEN H, ESKELINEN M, JARVINEN H, MECKLIN JP, DE LA CHAPELLE A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338: 1481-1487, 1998.
2. ALTER BP: Fanconi's anemia and malignancies. Am J Hematol 53: 99-110, 1996.
3. ALTER BP: Radiosensitivity in Fanconi's anemia patients. Radiother Oncol 62: 345-347, 2002.
4. ANDREASSEN PR, D'ANDREA AD, TANIGUCHI T: ATR couples FANCD2 monoubiquitination to the DNAdamage response. Genes Dev 18: 1958-1963, 2004.
5. AUDEH MW, CARMICHAEL J, PENSON RT, FRIEDLANDER M, POWELL B, BELL-MCGUINN KM, SCOTT C, WEITZEL JN, OAKNIN A, LOMAN N, LU K, SCHMUTZLER RK, MATULONIS U, WICKENS M, TUTT A: Oral poly(ADP ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251, 2010.
6. AUERBACH AD: Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 21: 731-733, 1993.
7. BARBER LJ, WARD TA, HARTLEY JA, MCHUGH PJ: DNA interstrand cross-link repair in the Saccharomyces cerevisiae cell cycle: overlapping roles for PSO2 (SNM1) with MutS factors and EXO1 during S phase. Mol Cell Biol 25: 2297-2309, 2005.
8. BARNES DE, LINDAHL T: Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38: 445-476, 2004.
9. BEN DAVID Y, CHETRIT A, HIRSH-YECHEZKEL G, FRIEDMAN E, BECK BD, BELLER U, BEN-BARUCH G, FISHMAN A, LEVAVI H, LUBIN F, MENCZER J, PIURA B, STRUEWING JP, MODAN B; NATIONAL ISRAELI STUDY OF OVARIAN CANCER: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20: 463-466, 2002.
10. BRANZEI D, FOIANI M: Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9: 297-308, 2008.
11. BRYANT HE, SCHULTZ N, THOMAS HD, PARKER KM, FLOWER D, LOPEZ E, KYLE S, MEUTH M, CURTIN NJ, HELLEDAY T: Specific killing of BRCA2-deficient tumourswith inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-916, 2005.
12. CANTOR S, DRAPKIN R, ZHANG F, LIN Y, HAN J, PAMIDI S, LIVINGSTONE DM: The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A 101: 2357-2362, 2004.
13. CONDIE A, POWLES RL, HUDSON CD, SHEPHERD V, BEVAN S, YUILLE MR, HOULSTON RS: Analysis of the Fanconi anaemia complementation group A gene in acute myeoloid leukaemia. Leuk Lymphoma 43: 1849-1853, 2002.
14. COUCH FJ, JOHNSON MR, RABE K, BOARDMAN L, MCWILLIAMS R, DE ANDRADE M, PETERSEN G: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65: 383-386, 2005.
15. D'ANDREA AD, GROMPE M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3: 23-34, 2003.
16. D'ANDREA AD: Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362: 1909-1919, 2010.
17. DE SILVA IU, MCHUGH PJ, CLINGEN PH, HARTLEY JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstand cross-links in mammalian cells. Mol Cell Biol 20: 7980-7990, 2000.
18. DERHEIMER FA, KASTAN MB: Multiple roles of ATM in monitoring and maintaining DNA intergrity. FEBS Lett 584: 3675-3681, 2010.
19. DHILLON VS, SHAHID M, HUSAIN SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 3: 33, 2004.
20. ELLEDGE SJ, AMON A: The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell 1: 129-132, 2002.
21. ENGELSTAEDTER V, CRISTEA MC, GARBER JE, NEUHAUSEN SL, FRANKEL PH, SAND S, STEELE L, MATULONIS U, LIU J, WEITZEL J: Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival. J Clin Oncol 28: 15s, 2010.
22. EVERS B, DROST R, SCHUT E, DE BRUIN M, VAN DER BURG E, DERKSEN PW, HOLSTEGE H, LIU X, VAN DRUNEN E, BEVERLOO HB, SMITH GC, MARTIN NM, LAU A, O'CONNOR MJ, JONKERS J: Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14: 3916-3925, 2008.
23. EVERS B, HELLEDAY T, JONKER J: Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 31: 372-380, 2010.
24. FARMER H, MCCABE N, LORD CJ, TUTT ANJ, JOHNSON DA, RICHARDSON TB, SANTAROSA M, DILLON KJ, HICKSON I, KNIGHTS C, MARTIN NMB, JACKSON SP, SMITH GCM, ASHWORT A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
25. FRIEDEL AM, PIKE BL, GASSER SM: ATR/Mec1: coordinating fork stability and repair. Curr Opin Cell Bio 21: 237-244, 2009.
26. FRIEDENSON B: BRCA1 and BRCA2 pathways and the risk o cancers other than breast or ovarian. MedGenMed 7: 60, 2005.
27. FRIEDBERG EC, AGUILERA A, GELLERT M, HANAWALT PC, HAYS JB, LEHMANN AR, LINDAHL T, LOWNDES N, SARASIN A, WOOD RD: DNA repair: from molecular mechanisms to human disease. DNA Repair (Amst) 5: 986-996, 2006.
28. GALLMEIER E, CALHOUN ES, RAGO C, BRODY JR, CUNNINGHAM SC, HUCL T, GOROSPE M, KOHLI M, LENGAUER C, KERN SE: Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 130: 2145-2154, 2006.
29. GALLMEIER E, HUCL T, BRODY JR, DEZENTJE DA, TAHIR K, KASPARKOVA J, BRABEC V, BACHMAN KE, KERN SE: High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res 67: 2169-2177, 2007a.
30. GALLMEIER E, KERN SE: Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther 4: 703-706, 2005.
31. GALLMEIER E, HUCL T, CALHOUN ES, CUNNINGHAM SC, BUNZ F, BRODY JR, KERN SE: Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 6: 654-660, 2007b.
32. GALLMEIER E, KERN SE: Targeting fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin Cancer Res 13: 4-9, 2007.
33. GOGGINS M, SCHUTTE M, LU J, MOSKALUK CA, WEINSTEIN CL, PETERSEN GM, YEO CJ, JACKSON CE, LYNCH HT, HRUBAN RH, KERN SE: Germline BRCA2ge ne mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360-5364, 1996.
34. GUINAN EC, LOPEZ KD, HUHN RD, FELSER JM, NATHAN DG: Evaluation of granulocyte-macrophage colonystimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr 14: 144-150, 1994.
35. HAHN SA, SCHUTTE M, HOQUE AT, MOSKALUK CA, DA COSTA LT, ROZENBLUM E, WEINSTEIN CL, FISCHER A, YEO CJ, HRUBAN RH, KERN SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
36. HAHN SA, GREENHALF B, ELLIS I, SINA-FREY M, RIEDER H, KORTE B, GERDES B, KRESS R, ZIEGLER A, RAEBURN JA, CAMPRA D, GRUTZMANN R, REHDER H, ROTHMUND M, SCHMIEGEL W, NEOPTOLEMOS JP, BARTSCH DK: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214-221, 2003.
37. HARFE BD, JINKS-ROBERTSON S: DNA mismatch repair and genetic instability. Annu Rev Genet 34: 359-399, 2000.
38. HARTWELL L, SZANKASI P, ROBERTS C, MURRAY A, FRIEND S: Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068, 1997.
39. HAZARD L: The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res 3: 20-28, 2009.
40. HELLEDAY T, LO J, VAN GENT DC, ENGELWARD BP: DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6: 923-935, 2007.
41. HOEIJMAKERS JHJ: Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374, 2001.
42. HOSOYA Y, LEFOR Y, HIRASHIMA Y, NOKUBI M, YAMAGUTI T, JINBU Y, MUROI K, NAKAZAWA M, YASUDA Y: Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. Jpn J Clin Oncol 40: 805-810, 2010.
43. HOUTSMULLER AB, RADEMAKERS S, NIGG AL, HOOGSTRATEN D, HOEIJMAKERS JH, VERMEULEN W: Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 284: 958-961, 1999.
44. HOWLETT NG, TANIGUCHI T, OLSON S, COX B, WAISFISZ Q, DE DIE-SMULDERS C, PERSKY N, GROMPE M, JOENJE H, PALS G, IKEDA H, FOX EA, D'ANDREA AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606-609, 2002.
45. HUCL T, RAGO C, GALLMEIER E, BRODY JR, GOROSPE M, KERN SE: A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 68: 5023-5030, 2008.
46. HUCL T, GALLMEIER E, KERN SE: Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Cell Cycle 6: 1336-1341, 2007.
47. ISHIAI M, KITAO H, SMOGORZEWSKA A, TOMIDA J, KINOMURA A, UCHIDA E, SABERI A, KINOSHITA E, KINOSHITA-KIKUTA E, KOIKE T, TASHIRO S, ELLEDGE SJ, TAKATA M: FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 15: 1138-1146, 2008.
48. JONES S, HRUBAN RH, KAMIYAMA M, BORGES M, ZHANG X, PARSONS DW, LIN JC, PALMISANO E, BRUNE K, JAFFEE EM, IACOBUZIO-DONAHUE CA, MAITRA A, PARMIGIANI G, KERN SE, VELCULESCU VE, KINZLER KW, VOGELSTEIN B, ESHLEMAN JR, GOGGINS M, KLEIN AP: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324: 217, 2009.
49. KAELIN WG: The concept of synthetic lethality in the context of anticancer therapy. Nature Rev Cancer 5: 689-698, 2005.
50. KALB R, DUERR M, WAGNER M, HERTERICH S, GROSS M, DIGWEED M, JOENJE H, HOEHN H, SCHINDLER D: Lack of sensitivity of primary Fanconi's anemia fibroblast to UV and ionizing radiation. Radiat Res 161: 318-325, 2004.
51. KENNEDY RD, D'ANDREA AD: DNA repair pathway in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24: 3799-3808, 2006.
52. KENNEDY RD, CHEN CC, STUCKERT P, ARCHILA EM, DE LA VEGA MA, MOREAU LA, SHIMAURA A, D'ANDREA AD: Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117: 1440-1449, 2007.
53. KING MC, MARKS JH, MANDELL JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646, 2003.
54. KNIPSCHEER P, RASCHLE M, SMOGORZEWSKA A, ENOIU M, HO TV, SCHARER OD, ELLEDGE SJ, WALTER JC: The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326: 1698-1701, 2009.
55. KONSTANTINOPOULOS PA, SPENTZOS D, KARLAN BY, TANIGUCHI T, FOUNTZILAS E, FRANCOEUR N, LEVINE DA, CANNISTRA SA: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561, 2010.
56. LEHMANN AR: Translesion synthesis in mammalian cells. Exp Cell Res 12: 2673-2676, 2006.
57. LEVITUS M, WAISISZ Q, GODTHELP BC, DE VRIES Y, HUSSAIN S, WIEGANT WW, ELGHALBZOURIMAGHRANI E, STELTENPOOL J, ROOIMANS MA, PALS G, ARWERT F, MATHEW CG, ZDZIENICKA MZ, HIOM K, DE WINTER JP, JOENJE H: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37: 934-935, 2005.
58. LINDAHL T, WOOD RD: Quality control by DNA repair. Science 286: 1897-1905, 1999.
59. LIU T, GHOSAL G, YUAN J, CHEN J, HUANG J: FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science 329: 693-696, 2010.
60. LODISH H: DNA replication, repair, and recombination. In: Molecular Cell Biology. LODISH H, BERK A, ZIPURSKY SL, MATSUDAIRA P, BALTIMORE D, DARNELL JE (eds), W.H. Freeman and Company, New York, 2000, pp 453-494.
61. MARSIT CJ, LIU M, NELSON JJ, POSNER M, SUZUKI M, KELSEY KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004, 2004.
62. MCMANUS KJ, BARRETT IJ, NOUHI Y, HIETER P: Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A 106: 3276-3281, 2009.
63. MIRCHANDANI KD, MCCAFFREY RM, D'ANDREA AD: The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) 7: 902-911, 2008.
64. MOLDOVAN GL, D'ANDREA AD: How the Fanconi anemia pathway guards the genome. Annu Rev Genet 43: 223-249, 2009.
65. MUKHOPADHYAY A, ALATTAR A, CERBINSKAITE A, WILKINSON SJ, DREW Y, KYLE S, LOS G, HOSTOMSKY Z, EDMONDSON RJ, CURTIN NJ: Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16: 2344-2351, 2010.
66. MURPHY KM, BRUNE KA, GRIFFIN N, SOLLENBERGER JE, PETERSEN GM, BANSAL R, HRUBAN RH, KERN SE: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17 %. Cancer Res 62: 3789-3793, 2002.
67. NACCARATI A, PARDINI B, HEMMINKI K, VODICKA P: Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res 635: 118-145, 2007.
68. NARAYAN G, ARIAS-PULIDO H, NANDULA SV, BASSO K, SUGIRTHARAJ DD, VARGAS H, MANSUKHANI M, VILLELLA J, MEYER L, SCHNEIDER A, GISSMANN L, DURST M, POTHURI B, MURTY VV: Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 64: 2994-2997, 2004.
69. O'DRISCOLL M, RUIZ-PEREZ VL, WOODS CG, JEGGO PA, GOODSHIP JA: A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33: 497-501, 2003.
70. PALAGYI A, NEVELING K, PLINNINGER U, ZIESCH A, TARGOSZ BS, DENK GU, OCHS S, RIZZANI A, MEIER D, THASLER WE, HANENBERG H, DE TONI EN, BASSERMANN F, SCHAFER C, GOKE B, SCHINDLER D, GALLMEIER E: Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinom a cell line HuH-7 confers sensitivity towards DNA-interstrand crossliniking agents. Mol Cancer 9: 127, 2010.
71. PEJOVIC T, YATES JE, LIU HY, HAYS LE, AKKARI Y, TORIMARU Y, KEEBLE W, RATHBUN RK, RODGERS WH, BALE AE, AMAZIANE N, ZWAAN CM, ERRAMI A, THUILLIER P, CAPPUCCINI F, OLSON SB, CAIN JM, BAGBY GC Jr: Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 66: 9017-9025, 2006.
72. RAHMAN N, SEAL S, THOMPSON D, KELLY P, RENWICK A, ELLIOTT A, REID S, SPANOVA K, BARFOOT R, CHAGTAI T, JAYATILAKE H, MCGUFFOG L, HANKS S, EVANS DG, ECCLES D, BREAST CANCER SUSCEPTIBILITY COLLABORATION, EASTON DF, STRATTON MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39: 165-167, 2007.
73. REID S, SCHINDLER D, HANENBERG H, BARKER K, HANKS S, KALB R, NEVELING K, KELLY P, SEAL S, FREUND M, WURM M, BATISH SD, LACH FP, YETGIN S, NEITZEL H, ARIFFIN H, TISCHKOWITZ M, MATHEW CG, AUERBACH AD, RAHMAN N: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162-164, 2007.
74. ROTHFUSS A, GROMPE M: Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA doublestrand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 24: 123-134, 2004.
75. SEAL S, THOMPSON D, RENWICK A, ELLIOTT A, KELLY P, BARFOOT R, CHAGTAI T, JAYATILAKE H, AHMED M, SPANOVA K, NORTH B, MCGUFFOG L, EVANS DG, ECCLES D; BREAST CANCER SUSCEPTIBILITY COLLABORATION (UK), EASTON DF, STRATTON MF, RAHMAN N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38: 1239-1241, 2006.
76. SIMON JA, SZANKASI P, NGUYEN DK, LUDLOW C, DUNSTAN HM, ROBERTS CJ, JENSEN EL, HARTWELL LH, FRIEND SH: Differentiall toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 60: 71-83, 1999.
77. STOEPKER C, HAIN K, SCHUSTER B, HILHORST-HOFSTEE Y, ROOIMANS MA, STELTENPOOL J, OOSTRA AB, EIRICH K, KORTHOF ET, NIEUWINT AW, JASPERS NG, BETTECKEN T, JOENJE H, SCHINDLER D, ROUSE J, DE WINTER JP: SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 43: 138-141, 2011.
78. TANIGUCHI T, D'ANDREA AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107: 4223-4233, 2006.
79. TANIGUCHI T, TISCHKOWITZ M, AMEZIANE N, HODGSON SV, MATHEW CG, JOENJE H, MOK SC, D'ANDREA AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574, 2003.
80. TISCHKOWITZ MD, SABBAGHIAN N, HAMEL N, BORGIDA A, ROSNER C, TAHERIAN N, SRIVASTAVA A, HOLTER S, ROTHENMUND H, GHADIRIAN P, FOULES WD, GALLINGER: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137: 1183-1186, 2009.
81. TORRANCE CJ, AGRAWAL V, VOGELSTEIN B, KINZLER KW: Use of isogenic human cancer cells for highthroughput screening and drug discovery. Nat Biotechnol 19: 940-945, 2001.
82. TUTT A, BERTWISTLE D, VALENTINE J, GABRIEL A, SWIFT S, ROSS G, GRIFFIN C, THACKER J, ASHWORTH A: Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20: 4704-4716, 2001.
83. VAN DER HEIJDEN MS, BRODY JR, GALLMEIER E, CUNNINGHAM SC, DEZENTJE DA, SHEN D, HRUBAN RH, KERN SE: Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165: 651-657, 2004.
84. VAN DER HEIJDEN MS, YEO CJ, HRUBAN RH, KERN SE: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63: 2585-2588, 2003.
85. VAN HAAFTEN G, VASTENHOUW NL, NOLLEN EAA, PLASTERK RHA, TIJSTERMAN M: Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality. Proc Natl Acad Sci U S A 101: 12992-12996, 2004.
86. VELAZQUEZ I, ALTER BP: Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 77: 257-267, 2004.
87. VOGELSTEIN B, KIZLER KW: Cancer gees ad the pathways they control. Nat Med 10: 789-799, 2004.
88. WILLINGHAM AT, DEVERAUX QL, HAMPTON GM, AZA-BLANC P: RNAi and HTS: exploring cancer by systematic loss-of-function. Oncogene 23: 8392-8400, 2004.
89. XIA B, DORSMAN JC, AMEZIANE N, DE VRIES Y, ROOIMANS MA, SHENG Q, PALS G, ERRAMI A, GLUCKMAN E, LLERA J, WANG W, LIVINGSTON DM, JOENJE H, DE WINTER JP: Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39: 159-161, 2007.
90. XIE Y, DE WINTER JP, WAISFISZ Q, NIEUWINT AW, SCHEPER RJ, ARWERT F, HOATLIN ME, OSSENKOPPELE GJ, SCHUURHUIS GJ, JOENJE H: Aberrant Fanconi Anaemia protein profiles in acute myeloid leukamia cells. Br J Haematol 111: 1057-1064, 2000.
91. YANG H, JEFFREY PD, MILLER J, KINNUCAN E, SUN Y, THOMA NH, ZHENG N, CHEN PL, LEE WH, PAVLETICH NP: BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297: 1837-1848, 2002.
92. ZHENG H, WANG X, WARREN AJ, LEGERSKI RJ, NAIRN RS, HAMILTON JW, LI L: Nucleotide excision repairand polymerase η-mediated error-prone removal of mitomycin C interstand cross-links. Mol Cell Biol 23: 754-761, 2003.